These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16149028)

  • 1. Investigation of the PADA as a method for monitoring GPIIb/IIIa inhibitors and other antiplatelet agents.
    Graff J; Harder S
    Semin Thromb Hemost; 2005; 31(4):482-5. PubMed ID: 16149028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is platelet adhesion assay able to quantify drug-induced platelet dysfunction?
    Schumann A; Bucha E; Nowak G
    Semin Thromb Hemost; 2005; 31(4):476-81. PubMed ID: 16149027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
    Klinkhardt U; Kirchmaier CM; Westrup D; Graff J; Mahnel R; Breddin HK; Harder S
    Clin Pharmacol Ther; 2000 Mar; 67(3):305-13. PubMed ID: 10741635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).
    Kottke-Marchant K; Powers JB; Brooks L; Kundu S; Christie DJ
    Clin Appl Thromb Hemost; 1999 Apr; 5(2):122-30. PubMed ID: 10725993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
    Harder S; Klinkhardt U; Graff J; Westrup D; Kirchmaier CM; Glusa E; Mascelli MA; Marciniak SJ; Just A; Lösche W; Breddin HK
    Thromb Res; 2001 Apr; 102(1):39-48. PubMed ID: 11323013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Platelet Adhesion Assay (PADA), a new quantitative test for assessment of platelet function and therapeutic drug monitoring of GPIIb/IIIa and ADP receptor antagonists].
    Schumann A; Wiesenburg A; Bucha E; Nowak G
    Hamostaseologie; 2004 Aug; 24(3):211-6. PubMed ID: 15314708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.
    Reiter RA; Mayr F; Blazicek H; Galehr E; Jilma-Stohlawetz P; Domanovits H; Jilma B
    Blood; 2003 Dec; 102(13):4594-9. PubMed ID: 12920042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet function tests and flow cytometry to monitor antiplatelet therapy.
    Matzdorff A
    Semin Thromb Hemost; 2005; 31(4):393-9. PubMed ID: 16149015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
    Schrör K
    Herz; 2001 Apr; 26 Suppl 1():30-5. PubMed ID: 11349624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin.
    Schneider DJ; Baumann PQ; Holmes MB; Taatjes DJ; Sobel BE
    Thromb Haemost; 2001 Feb; 85(2):309-13. PubMed ID: 11246553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
    Wang X; Dorsam RT; Lauver A; Wang H; Barbera FA; Gibbs S; Varon D; Savion N; Friedman SM; Feuerstein GZ
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1114-20. PubMed ID: 12438534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S; Lassila R
    Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability.
    Speich HE; Furman RR; Lands LT; Moodie GD; Jennings LK
    J Thromb Thrombolysis; 2013 Jul; 36(1):31-41. PubMed ID: 23073747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A; Voss R
    Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists.
    Storey RF; Wilcox RG; Heptinstall S
    Circulation; 1998 Oct; 98(16):1616-21. PubMed ID: 9778326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.